Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 196

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 196
---
 preferred units into Longevity common stock           |     |   |    (470,000 | ) |
| Elimination of historical members’ deficit                          |     |   |     794,247 |   |
| Additional paid-in capital resulting from the issuance of Longevity |     |   |             |   |
| common stock                                                        |     |   |  45,276,216 |   |
| Adjustment to accumulated deficit for IPR&D                         |     | $ | (45,455,950 | ) |

| (C) | To reflect the elimination of related party accounts payable and receivable as a result of the acquisitions. |

| (D) | To reflect the reverse acquisition of Longevity, including the elimination of its accumulated deficit. |

| 92 |

Target Acquisitions Statement of Operations Pro Forma Adjustments

| (E) | To reflect the change in outstanding shares of Longevity as a result of the acquisitions resulting in 
 the total shares outstanding in the combined entity of 9,217,200 shares.                              |

| (G) | To eliminate the income and expense associated with the management services agreement between Longevity 
 and Cerevast.                                                                                           |

Note 4 — Target Acquisitions
Net Loss per Share

Represents the
net loss per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection
with the Target Acquisitions, assuming the shares were outstanding since January 1, 2023. As the Target Acquisitions and related equity
transactions are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average
shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Target Acquisitions have
been outstanding for the entirety of the period presented.

|                                                     |     |   | For the Nine Months Ended September 30, 2024 |   |     |   | For the Year Ended December 31, 2023 |   |
|:----------------------------------------------------|:----|:--|---------------------------------------------:|:--|:----|:--|-------------------------------------:|:--|
| Pro forma net loss                                  |     | $ |                                   (5,107,630 | ) |     | $ |                          (54,902,804 | ) |
| Weighted average shares of common stock outstanding |     |   |                                    9,217,200 |   |     |   |                            9,217,200 |